United Therapeutics Q2 2026 Earnings Report

United Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: $6.92
• Beat/Miss: N/A
• One Year Ago EPS: N/A

United Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $807.68 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

United Therapeutics Announcement Details

• Quarter: Q2 2026
• Date: 7/29/2026
• Time: Before Market Opens
• Conference Call Date: Wednesday, July 29, 2026
• Conference Call Time: 9:00AM ET

United Therapeutics (NASDAQ:UTHR) (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs. In addition to its PAH portfolio, United Therapeutics markets dinutuximab (Unituxin) for high-risk neuroblastoma and continues to expand its therapeutic reach through ongoing clinical programs.

Founded in 1996 and headquartered in Silver Spring, Maryland, United Therapeutics has combined its core expertise in vascular biology with innovative manufacturing technologies. Beyond pharmaceuticals, the company’s Lung Biotechnology PBC subsidiary explores regenerative medicine approaches, including decellularized and recellularized organ scaffolds and xenotransplantation methods aimed at addressing organ shortages. Its research pipeline encompasses next-generation agents for PAH, oncology, and transplant applications, reflecting a broad commitment to extending and improving life for patients with complex diseases.

United Therapeutics operates globally, with commercial and clinical efforts spanning North America, Europe, and Asia. Its international infrastructure supports regulatory submissions and patient access programs in key markets such as the European Union and Japan. Under the leadership of founder and Chief Executive Officer Martine Rothblatt, the company emphasizes a multidisciplinary culture that integrates basic science, engineering and patient advocacy. This approach drives its mission to pioneer transformational therapies and sustainable organ manufacturing technologies for conditions with high unmet medical need.